Nothing Special   »   [go: up one dir, main page]

DE60117096D1 - Dihydroindol- und tetrahydrochinolinderivate - Google Patents

Dihydroindol- und tetrahydrochinolinderivate

Info

Publication number
DE60117096D1
DE60117096D1 DE60117096T DE60117096T DE60117096D1 DE 60117096 D1 DE60117096 D1 DE 60117096D1 DE 60117096 T DE60117096 T DE 60117096T DE 60117096 T DE60117096 T DE 60117096T DE 60117096 D1 DE60117096 D1 DE 60117096D1
Authority
DE
Germany
Prior art keywords
dihydroindol
tetrahydrochinoline
derivatives
tetrahydrochinoline derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60117096T
Other languages
English (en)
Other versions
DE60117096T2 (de
Inventor
Johannes Aebi
Jean Ackermann
Alexander Chucholowski
Henrietta Dehmlow
Olivier Morand
Sabine Wallbaum
Thomas Weller
Narendra Panday
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of DE60117096D1 publication Critical patent/DE60117096D1/de
Application granted granted Critical
Publication of DE60117096T2 publication Critical patent/DE60117096T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20Oxygen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10Antimycotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/14Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)
DE60117096T 2000-12-21 2001-12-12 Dihydroindol- und tetrahydrochinolinderivate Expired - Lifetime DE60117096T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP00128063 2000-12-21
EP00128063 2000-12-21
PCT/EP2001/014620 WO2002050041A1 (en) 2000-12-21 2001-12-12 Dihydroindole and tetrahydroquinoline derivatives

Publications (2)

Publication Number Publication Date
DE60117096D1 true DE60117096D1 (de) 2006-04-20
DE60117096T2 DE60117096T2 (de) 2006-11-23

Family

ID=8170751

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60117096T Expired - Lifetime DE60117096T2 (de) 2000-12-21 2001-12-12 Dihydroindol- und tetrahydrochinolinderivate

Country Status (15)

Country Link
US (2) US6706751B2 (de)
EP (1) EP1358162B1 (de)
JP (1) JP4068459B2 (de)
KR (1) KR100530408B1 (de)
CN (1) CN1208322C (de)
AR (1) AR035408A1 (de)
AT (1) ATE317386T1 (de)
AU (2) AU2002219176B2 (de)
BR (1) BR0116263A (de)
CA (1) CA2431100C (de)
DE (1) DE60117096T2 (de)
ES (1) ES2257381T3 (de)
MX (1) MXPA03005395A (de)
WO (1) WO2002050041A1 (de)
ZA (1) ZA200304646B (de)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20040522A1 (es) 2002-05-29 2004-09-28 Novartis Ag Derivados de diarilurea dependientes de la cinasa de proteina
NZ538031A (en) * 2002-08-29 2007-10-26 Merck & Co Inc Indoles having anti-diabetic activity
TW200510271A (en) * 2003-08-08 2005-03-16 Ube Industries Alkynyl substituded condensed heterocyclic compound, method for producing the same and organic electroluminescence element using the same
TWI329102B (en) * 2006-08-15 2010-08-21 Nat Health Research Institutes Thiourea compounds and method for inhibiting hepatitis c virus infection
WO2008124300A1 (en) * 2007-04-10 2008-10-16 National Health Research Institutes Hepatitis c virus inhibitors
US7897764B2 (en) * 2007-06-08 2011-03-01 National Health Research Institutes Thiourea derivatives
TWI361808B (en) * 2008-01-08 2012-04-11 Nat Health Research Institutes Imidazolidinone and imidazolidinethione derivatives
US8198284B2 (en) * 2008-04-30 2012-06-12 National Health Research Institutes Treatment of neurodegenerative disorders with thiourea compounds

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3997542A (en) * 1975-06-23 1976-12-14 Sterling Drug Inc. 1-(Halogenated-acetyl)-1,2,3,4-tetrahydro-6-quinolinols and esters thereof
NZ227042A (en) 1987-11-27 1991-05-28 Banyu Pharma Co Ltd Substituted alkylamine derivatives and pharmaceutical compositions
US5288749A (en) 1991-12-20 1994-02-22 Abbott Laboratories Tertiary and secondary amines as alpha-2 antagonists and serotonin uptake inhibitors
TW438774B (en) 1993-07-14 2001-06-07 Hoffmann La Roche Pharmaceutical composition for lowering cholesterol containing phenalkylamines and certain novel phenalkylamines
US6313127B1 (en) 1996-02-02 2001-11-06 Zeneca Limited Heterocyclic compounds useful as pharmaceutical agents
DE19727117A1 (de) 1997-06-26 1999-01-07 Boehringer Ingelheim Pharma Phenylalkylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
CA2408913A1 (en) 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Melanin-concentrating hormone antagonist

Also Published As

Publication number Publication date
CA2431100A1 (en) 2002-06-27
US20050020624A1 (en) 2005-01-27
US20030004156A1 (en) 2003-01-02
KR100530408B1 (ko) 2005-11-22
JP2004519441A (ja) 2004-07-02
EP1358162A1 (de) 2003-11-05
US6706751B2 (en) 2004-03-16
ZA200304646B (en) 2004-09-13
AR035408A1 (es) 2004-05-26
AU2002219176B2 (en) 2006-02-09
CA2431100C (en) 2009-03-24
JP4068459B2 (ja) 2008-03-26
CN1208322C (zh) 2005-06-29
DE60117096T2 (de) 2006-11-23
EP1358162B1 (de) 2006-02-08
MXPA03005395A (es) 2003-09-25
CN1481366A (zh) 2004-03-10
ES2257381T3 (es) 2006-08-01
ATE317386T1 (de) 2006-02-15
BR0116263A (pt) 2003-12-30
WO2002050041A1 (en) 2002-06-27
AU1917602A (en) 2002-07-01
KR20030063453A (ko) 2003-07-28
US7102007B2 (en) 2006-09-05

Similar Documents

Publication Publication Date Title
DK1292604T3 (da) 2-Aminocarbonyl-9H-purinderivater
DE50112013D1 (de) Deodorantien und antiperspirantien
IS6385A (is) Ný notkun og nýjar N-asabísýkló-amíð afleiður
AR028343A1 (es) Derivados de pirrolidina y piperidina
ATE540013T1 (de) Naphthalinderivate
EE200300071A (et) Kinasoliini derivaadid
ATE288437T1 (de) Tetrahydro-heterocycloazepinyl-pyrimidin-deriva e
ATE298332T1 (de) Decahydro-isochinolinderivate
DK1280809T3 (da) Antitumorecteinascidinderivater
NO20025510L (no) Dibenzoazulen-derivater samt anvendelse derav
DK1571140T3 (da) Substituerede C-cyjklohexylmethylamin-derivater
AR028602A1 (es) Derivados de pirrol
AR028282A1 (es) Derivados de aminofenil pirimidona
DE60032898D1 (de) Arylthiazolidindion- und aryloxazolidinderivate
DK1322593T3 (da) O-substituerede-6-methyl-tramadol-derivater
ATE282021T1 (de) Substituierte aminomethyl-phenyl- cyclohexanderivate
DE50113112D1 (de) Schaltungsanordnung
DE60117096D1 (de) Dihydroindol- und tetrahydrochinolinderivate
ATE280752T1 (de) Aminomethyl-phenyl-cyclohexanonderivate
NO20024617L (no) Aryl- og heteroarylsulfonater
ATE299873T1 (de) Substituierte c-furan-2-yl-methylamin- und c- thiophen-2-yl-methylamin-derivate
DE50112454D1 (de) Substituierte 5-amino-1-penten-3-ol-derivate
DE60118970D1 (de) Indol- und dihydroindolderivate
ATE374776T1 (de) Pyrrolotriazolopyrimidinonderivate
NO20024393D0 (no) 2-fenylpyran-4-on-derivater

Legal Events

Date Code Title Description
8364 No opposition during term of opposition